

Allegato B

Laura D'Erasmus
Curriculum Vitae

Place Rome

Date 21 June 23

Part I – General Information

Full Name	Laura D'Erasmus
-----------	-----------------

Part II – Education

Type	Year		Institution	Notes (Degree, Experience,...)
University graduation	2002	2007	Sapienza, University of Rome	Medical Doctor degree Thesis title: “OBESITA' E SINDROME METABOLICA: LA PREDISPOSIZIONE GENETICA INFLUENZA LA RISPOSTA TERAPEUTICA?” with a vote of 110\110 with Honors
Specialty	2008	2013	Sapienza, University of Rome	Internal Medicine Residency Degree Thesis title:” EFFETTO DELLA VARIANTE I148M DEL GENE PNPLA3 NELL'INFLUENZARE IL FENOTIPO METABOLICO E VASCOLARE IN PAZIENTI CON STEATOSI EPATICA” with a vote of 70\70 with Honors
PhD	2013	2017	Sapienza, University of Rome	PhD degree in Tecnologie Biomediche Innovative in Medicina clinica Thesis title: “Investigation on cardiovascular outcomes and clinical management of severe hypercholesterolemia phenotypes” with Honors
Post-graduate studies				
Pre-doctorate training				
Licensure 01	2008	ongoing	Sapienza, University of Rome	Licensed to practice as Medical Doctor and Surgeon. ID number: 56319

Licensure 02	2022	2033	Ministero dell'Università e della Ricerca	National scientific qualification as Associate Professor. 06/B1- Medicina Interna (decreto direttoriale n. 553/2021 come rettificato con decreto direttoriale n. 589/2021)
--------------	------	------	---	---

Part III – Appointments

III A – Academic Appointments

Start	End	Institution	Position
01 June 2017	31 May 2018	Department of Internal Medicine and Allied Specialties, Sapienza, University of Rome	Research fellowship with the title “Studio della prevalenza di danno coronarico e steatosi epatica in soggetti da ipolipidemia da deficit di ANGPTL3” SSD MED/09 (art. 22, Legge 240/2010)
01 June 2018	31 May 2019	Department of Internal Medicine and Allied Specialties, Sapienza, University of Rome	Research fellowship with the title “Studio della prevalenza di danno coronarico e steatosi epatica in soggetti da ipolipidemia da deficit di ANGPTL3” SSD MED/09 (art. 22, Legge 240/2010)
01 June 2019	31 May 2020	Department of Internal Medicine and Allied Specialties, Sapienza, University of Rome	Research fellowship with the title “Studio della prevalenza di danno coronarico e steatosi epatica in soggetti da ipolipidemia da deficit di ANGPTL3” SSD MED/09 (art. 22, Legge 240/2010)
01 June 2020	11 Jan 2022	Department of Translational and Precision Medicine, Sapienza, University of Rome	Research fellowship with the title “Studio della prevalenza di danno coronarico e steatosi epatica in soggetti da ipolipidemia da deficit di ANGPTL3” SSD MED/09 (art. 22, Legge 240/2010). This contract has been extended for the maternity leave (from 08 September 2020 to 21 April 2021)
12 January 2022	11 January 2023	Department of Translational and Precision Medicine, Sapienza, University of Rome	Research fellowship with the title “Studio della prevalenza di danno coronarico e steatosi epatica in soggetti da

12 January 2023	ongoing	Department of Translational and Precision Medicine, Sapienza, University of Rome	ipolipidemia da deficit di ANGPTL3” SSD MED/09 (art. 22, Legge 240/2010)
			Research fellowship with the title “Studio della prevalenza di danno coronarico e steatosi epatica in soggetti da ipolipidemia da deficit di ANGPTL3” SSD MED/09 (art. 22, Legge 240/2010)

IIIB – Other Appointments

Start	End	Institution	Position
January 2018	August 2019	Department of Internal Medicine, Erasmus MC University Medical Center, 3015 GD, Rotterdam, Netherlands (Prof. JR Van Lennepe)	Researcher supported by Amryt Pharmaceuticals DAC (unrestricted grant)
October 2019	March 2020	Department of Endocrinology and Prevention of Cardiovascular Disease, Pitié-Salpêtrière University Hospital, Paris, France (Prof. Eric Bruckert, Prof. Antonio Gallo)	Visiting researcher by Amryt Pharmaceuticals DAC (unrestricted grant)
April 2020	September 2021	Department of Endocrinology and Prevention of Cardiovascular Disease, Pitié-Salpêtrière University Hospital, Paris, France (Prof. Eric Bruckert, Prof. Antonio Gallo)	Researcher supported by Amryt Pharmaceuticals DAC (unrestricted grant)
January 2022	August 2022	Department of Internal Medicine, Erasmus MC University Medical Center, 3015 GD, Rotterdam, Netherlands (Prof. JR Van Lennepe)	Researcher supported by Amryt Pharmaceuticals DAC (unrestricted grant)

IIIC – Editorial Responsibilities

2020	Nutrition Metabolism and Cardiovascular Disease	Associate Editor
2021	Atherosclerosis Plus	Editorial Board Member
2022	Biomedicines	Guest Editor for the Special Issue “Metabolic and Genetic Associated Fatty Liver Diseases”

IIID-Others certificates

25 May 2023	ongoing	The Global Health Network	Good Clinical Practice Certificate acquisition
10 February 2023	ongoing	American Heart Association	Basic Life Support (CPR and AED) provider certificate acquisition

IV-Participation in Clinical Trials

I have participated as Sub-investigator to at least 22 sponsored trials and 6 investigator-driven studies.

The complete list of studies and their code/name is reported below:

1. CTQJ230A12301
2. Heritage_CTQJ230A12001
3. ORION-16_CKJX839C12301
4. Regeneron-CL-1643
5. R1500-HTG-1522
6. HTG R1500-20118
7. Omero Study
8. AMGEN 20120124
9. AMGEN 20120123
10. ISIS 304801-CS7
11. ISIS 304801-CS6
12. ISIS 678354-CS13
13. ISIS 678354-CS5
14. CKJX839C12001B
15. Amgen 20210057
16. Amgen 20180244
17. Trial clinico sponsorizzato Lochness (EudraCT number: 2018-002911-80)
18. Geniall di registro "GENIALL Lipoprotein Lipase Deficiency (LPLD) Disease Registry"
19. Studio di registro Lower
20. Studio Prior
21. Studio SANTORINI
22. Studio MILOS
23. Studio clinico collaborativo internazionale sulla HoFH (HICC) -una piattaforma globale di condivisione dati
24. Studio Lipigen (LIPid transport disorders Italian GENetic Network)
25. Studio Valutazione dell'efficacia della lomitapide nel ridurre i livelli di colesterolemia LDL ed incidenza di eventi cardiovascolari in pazienti affetti da Ipercolesterolemia Familiare omozigote: analisi retrospettiva di una coorte europea.
26. Studio comparativo del metabolismo postprandiale delle lipoproteine in pazienti con NAFLD determinata metabolicamente o geneticamente
27. Studio della prevalenza di danno coronarico e steatosi epatica in soggetti da ipolipidemia da deficit di ANGPTL3
28. Studio cinetico in-vivo delle lipoproteine contenenti apoB in soggetti con deficit di ANGPTL3

Part V – Teaching experience

Year	Institution	Lecture/Course
18 March 2022	Percorsi per le Competenze Trasversali e per l'Orientamento (PCTO, ex Alternanza Scuola Lavoro), AA 2021- 2022.	Cosa fare in caso di... essere medico o infermiere
03 July 2018	Sapienza, University of Rome, Specializzazione in Patologia Clinica	La medicina di laboratorio applicata alla pratica Clinica

	e Biochimica Clinica	
05 May 2017	Sapienza, University of Rome, Specializzazione in Patologia Clinica e Biochimica Clinica	La medicina di laboratorio applicata alla pratica Clinica
28 April 2016	Sapienza, University of Rome, Specializzazione in Patologia Clinica e Biochimica Clinica	La medicina di laboratorio applicata alla pratica Clinica
14 May 2015	Sapienza, University of Rome, Specializzazione in Patologia Clinica e Biochimica Clinica	La medicina di laboratorio applicata alla pratica Clinica

Part VI - Society memberships, Awards and Honors

Year	Title
From 2010 to date	Member of the Italian Society of Atherosclerosis
From 2010 to date	Member of the Italian Society of Internal Medicine
From 2012	Member of the European Atherosclerosis Society
23 October 2022	“Mario Condorelli Award”, from the Italian Society of Internal Medicine for the article “D’Erasmus L, Minicocci I, Di Costanzo A, et al. Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Long-Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events. J Am Heart Assoc. 2021;10(9):e018932. doi:10.1161/JAHA.120.018932”
26 October 2021	Recognition in the volume “Paladini Italiani della Salute” for the achievement of important result in medical research for the article “D’Erasmus L, Minicocci I, Nicolucci A, et al. Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes. J Am Coll Cardiol. 2018;71(3):279-288 (from Associazione Liber, event sponsored by the Senate of the Italian Republic, Presidency of the Council, Ministry of the Interior, Ministry of Economic Development, Ministry of Health, Ministry of Cultural Heritage, Ministry of Agricultural Food and Forestry Policies, Ministry of the Environment, Ministry of Labour and Social Policy, Ministry of Infrastructure and Transport, Ministry of Education, University and Research, Istituto Superiore di Sanità)
01 June 2016	“Best young Investigator Presentation Award” from the European Atherosclerosis Society
2023	Young Italian Atherosclerosis Society Group Social Supervision Committee
2022	Contribution to draft the Consensus paper on “Ipercolesterolemia familiare in forma eterozigote ed omozigote” promoted by the Italian Society of Atherosclerosis (SISA) and SISA foundation

Part VII Institutional Responsibility

2020-2022	Member of the Local (Lazio) Executive Committee of the Italian Atherosclerosis Society
2020-2022	Member of the Executive Coordinating Committee of Young Italian

	Atherosclerosis Society group
2022-ongoing	Member of the Executive Committee of the Italian Society of Atherosclerosis
2022	Member of the coordinating team of researcher working on homozygous familial hypercholesterolemia within the LIPIGEN study supported by SISA Foundation

Part VIII – Scientific Meeting

VIIIA-Organization of Scientific Meetings

2023	Member of the organizing committee for the 2024 Congress of the European Atherosclerosis Society
2023	Member of the logistic organizing committee for the 2023 Congress of the Italian Society of Atherosclerosis

VIIIB-Participation to scientific meeting as invited speaker or chairman/moderator

11/11/2023	Invited speaker for the “Simposio AME-SISA” during the national congress of the Associazione Medici Endocrinologi (AME)
21-22/06/2023	Moderator at the “7° CORSO AVANZATO DI LIPIDOLOGIA CLINICA” organized by the Italian Society of Atherosclerosis
21-24/05/2023	SAAG moderator at the 2023 European Atherosclerosis Society Congress
8/06/2023	Invited speaker “LA GIORNATA DELL'INTERNISTA - LA PREVENZIONE CARDIOVASCOLARE” organized by the Italian Society of Internal Medicine with the patronage of the Policlinico Umberto I, Sapienza University of Rome
17-18/05/2023	Invited speaker “HoFH2days” (sponsored event)
14/4/2023	Invited speaker and Chairman “1st Permanent Academy on Cardiometabolic Prevention in Clinical Practice” sponsored by the Italian Society of Hypertension
3/5/2023	Invited speaker for the course “Why do clinicians need to know about rare lipid disorders?” organized by the European Atherosclerosis Society
10-11/3/2023	Invited speaker “LA TERAPIA ANTICOAGUANTE E LA TERAPIA IPOLIPEMIZZANTE NEI CONTESTI CLINICI AD ELEVATO” (sponsored event)
27-29/11/2022	Invited speaker “National Congress of the Italian Society of Atherosclerosis”
17/11/2022	Invited speaker “PREVENZIONE E CURA DELLE MALATTIE CARDIOVASCOLARI Invited speaker “(sponsored event)
02/11/2022-16/12/2022	Speaker and teaching experience for the “PRECEPTORSHIP ON Familial Chylomicronemia Syndrome (FCS) ” (sponsored event)
27/10/22	Invited speaker “X SIMPOSIO SCIENTIFICO CARDIO UPDATE 2022”
30/9/2022-1/10/2022	Invited speaker “CONGRESSO REGIONALE S.I.S.A. SEZIONE LAZIO” organized by the local committee of the Italian Society of Atherosclerosis
15-16/09/2022	Invited speaker “La roadmap della prevenzione cardiovascolare” (sponsored event)
7-9/7/2022	Invited speaker at the “6° CORSO AVANZATO DI LIPIDOLOGIA

	CLINICA” organized by the Italian Society of Atherosclerosis
10/03/2022	Invited speaker “Complessità in campo di Arteriopatia Periferica” (sponsored event)
28-30/11/2021	Invited speaker “National Congress of the Italian Society of Atherosclerosis” (virtual event)
9/10/2021	Invited speaker “CONGRESSO REGIONALE S.I.S.A. SEZIONE LAZIO” organized by the local committee of the Italian Society of Atherosclerosis
17-18/9/2021	Invited speaker for the “XV CONGRESSO SIMI SEZIONE LAZIO MOLISE” organized by the Italian Society of Internal Medicine
1-3/7/2021	Invited speaker for the digital edition of the “CORSO AVANZATO DI LIPIDOLOGIA CLINICA” organized by the Italian Society of Atherosclerosis
01/06/2021	Invited Speaker "The changing face of HoFH" sponsored session during the European Atherosclerosis Society
20-21/05/2021	Chairman and abstract reviewer at the Spring Meeting Conference of the Italian Society of Atherosclerosis
22/11/2020-22/2/2021	Invited Speaker for the FAD “La sindrome chilomicronemica familiare (FCS): una luce in fondo al tunnel” during the National Congress of the Italian Society of Atherosclerosis (virtual event)
4-7/10/2020	Invited Speaker "The changing face of HoFH" sponsored session during the European Atherosclerosis Society
2/7/2020	Chairman at the Spring Meeting Conference of the Italian Society of Atherosclerosis
3/4/2020	Invited speaker for the joined event SISA-FADOI “LA GESTIONE CLINICA DELLE DISLIPIDEMIE PER LA PREVENZIONE CARDIOVASCOLARE”
24-29/11/2019	Invited speaker “National Congress of the Italian Society of Atherosclerosis”
18/6/2019-15/10/2019	Invited Speaker “FAD FCS ways: competenze cliniche a confront per una corretta diagnosi della syndrome chilomicronemica familiare” (sponsored event)
12-19/9/2019	Invited Speaker “Navigating the Medical Labyrinth of HoFH” international course (sponsored event)
4-6/10/2019	Invited Speaker “CORSO AVANZATO SULLE MALATTIE RARE DEL METABOLISMO” with the patronage of the Italian Society of Atherosclerosis, Regione Siciliana, Azienda Ospedaliero Universitaria Paolo Giaccone (Palermo)
11/06/2019	Invited speaker “CORSO AVANZATO IN LIPIDOLOGIA CLINICA. Le principali sindromi dislipidemiche: dalla clinica alla diagnosi molecolare”, II meeting (sponsored event)
14-15/6/2019	Invited speaker “Appropriatezza e continuità assistenziale in prevenzione cardiovascolare: una scelta con il paziente al centro” (sponsored event)
04/04/2019	Invited speaker “CORSO AVANZATO IN LIPIDOLOGIA CLINICA. Le principali sindromi dislipidemiche: dalla clinica alla diagnosi molecolare”, I meeting (sponsored event)
25-27/11/2018	Invited speaker “National Congress of the Italian Society of Atherosclerosis”
24/09/2019	Invited speaker “52° CONVEGNO CARDIOLOGIA 2018”

21-22/9/2018	Invited speaker “CONGRESSO INTERREGIONALE SISA SEZIONE SICILIA-CALABRIA” organized by the local committee of the Italian Society of Atherosclerosis
07/04/2018	Invited speaker “IX CONGRESSO NAZIONALE ACSA - I RITMI DELLA VITA”
19-21/9/2017	Invited speaker “National Congress of the Italian Society of Atherosclerosis”

Part IX-Funding Information [grants as PI-principal investigator or I-investigator]

Year	Title	Program	Grant value
2016	Targeted sequencing of LPL, APOCII, APOA5, GPIHBP1 and LMF1 genes in individuals with severe hypertriglyceridemia and/or acute pancreatitis	Starting grant	
2021	Studio multicentrico osservazionale di valutazione dell'efficacia della terapia con lomitapide nel migliorare il profilo lipidico e ridurre l'incidenza di eventi cardiovascolari in pazienti affetti da ipercolesterolemia familiare omozigote: analisi retrospettiva di una coorte europea	Starting grant	
2022	Efficacy of Long-term treatments of Autosomal recessive hypercholesterolemia (ARH) with lomitapide: a sub-analysis of the Pan European cohort	Starting grant	

Part X – Research Activities

Keywords	Brief Description
Familial Combined Hypolipidemia (FHBL2)	<p>This topic is one of the most important research activities in my working experience. I have been involved in several research and publications since 2017 to date. I am actively involved in <i>in vivo</i> and <i>in vitro</i> studies focused at increasing the knowledge of the role of angiopoietins in lipid trafficking and energy balance. To date I have published 12 papers on this research: 3 reviews, 1 book chapter and 8 original articles (1 as corresponding, 2 as first and 1 as last author).</p> <p>The main collaboration was with the Washington University, St. Louis, MO (Prof. N. Stitzel). Data obtained by this collaboration are of great interest especially for the possibility of using Angptl3 as a</p>

	<p>potential target for the treatment of disturbances of lipid metabolism and atherosclerosis. Results of this collaborative international work have been included in a manuscript, for which I am first author, that is currently under the revision on Circulation (IF 39.922).</p> <p>Another important need is to establish the role of Angpt3 in lipoprotein trafficking. To uncover the role of Angpt3 in chylomicron and VLDL metabolism in humans we are currently conducting a post-prandial kinetic study using stable isotopes on FHBL2. This work is performed in collaboration with University of Helsinki, Helsinki, Finland and University of Gothenburg, Gothenburg, Sweden.</p>
Hypertriglyceridemia	<p>Assessment of the association between mild to moderate hypertriglyceridemia and cardiovascular risk (Arca M, Veronesi C, D'Erasmus L, Borghi C, Colivicchi F, De Ferrari GM, Desideri G, Pontremoli R, Temporelli PL, Perrone V, Degli Esposti L; Local Health Units Group †. Association of Hypertriglyceridemia with All-Cause Mortality and Atherosclerotic Cardiovascular Events in a Low-Risk Italian Population: The TG-REAL Retrospective Cohort Analysis. J Am Heart Assoc. 2020 Oct 20;9(19):e015801)</p>
Monogenic and multifactorial hyperchylomicronemia	<p>I have collected several experienced in diagnosing and treating both monogenic and polygenic hyperchylomicronaemia. The effort is to dissect between different form of severe hypertriglyceridemia by individualizing treatment and management in a precision medicine approach. The efforts lead to several national and international publication for a total of 8 papers: 4 reviews and 4 original articles (4 as first author). This topic is part of several national and international collaboration in which I am currently actively involved.</p>
Familial Hypercholesterolemia	<p>This research activity is mainly focused in the diagnosis and cardiovascular risk stratification in patients with hypercholesterolemia, both monogenic and polygenic. I have published focused 7 paper (2 as first author), also through national collaboration among the LIPid transport disorders Italian Genetic Network (LIPIGEN).</p>
Homozygous Familial Hypercholesterolemia	<p>This topic is one of the most important research activities in my working experience as most of the international collaboration and results have been reached working on this topic. Results of the coordinating activity I was intitled by Prof. JR Van Lennep, Prof. E. Brucker and Prof. A. Gallo had a strong impact on the scientific community as</p>

Autosomal Hypercholesterolemia	Recessive	<p>demonstrated by the fact that these works were cited in the last consensus on HoFH published by the European Atherosclerosis Society (Eur Heart J. 2023 May 2;ehad197.). The data collected as coordinating team of the LIPIGEN study have been also included in a manuscript that can be considered as one of the milestones in the description of the natural history of homozygous hypercholesterolemia in which I am listed as co-authors (Lancet. 2022 Feb 19;399(10326):719-728). Of note, the contribution to the HICC registry is resulting in several other manuscript that are under preparation: one on the impact of lipoprotein apheresis in the management of HoFH and the other on the sex differences between HoFH. Overall, from 2017 to date, I published 2 reviews and 7 original articles (5 as first authors)</p>
Non-alcoholic fatty liver disease		<p>This topic is an important part of my career as during my PhD I led a worldwide collection of patients suffering with ARH and results were published on J Am Coll Cardiol. Subsequently, I have been invited to write a review article on ARH. More recently, I performed a sub-analysis of the pan European study focused at evaluating the efficacy and safety of lomitapide in ARH patients which results were recently published on Front Genet. For these publications I am the first author.</p>
Real world efficacy and safety of lipid lowering drugs		<p>These research activities are mainly focused on the understanding of the role of metabolic and genetic factors in non-alcoholic fatty liver disease (NAFLD) and at evaluating differences in their clinical consequences (progression to liver diseases as well as atherosclerotic cardiovascular disease—ASCVD). On this topic I have published 10 papers: 8 original article, 1 systematic review and 1 review (3 as first author).</p> <p>This research activity is based on the need to verify the real-world safety and efficacy of drugs used to treat common and severe disease of lipid metabolism. On this topic I have published several article mainly on rare disease such as HoFH or FCS. Of note, I was recently involved in a collaborative work with AIFA aimed at evaluating the efficacy and safety of monoclonal antibodies directed towards PCSK9i in the large population of HeFH patients included in the AIFA monitoring registries.</p>

Part XI – Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
Papers [international]	62	Scopus	2012	2023

	61	Scopus	2013	2023
Papers [national]				
Books [scientific]				
Books [teaching]				

Total Impact factor	For the entire publications production:510,58 (JCR, Clarivate)
	For the 12 significant publications: 86,15 (JCR, Clarivate)
Total Citations	1106,0 (Scopus)
Average Citations per Product	17,83 (Scopus) from 2012 to 2023
	18,13 (Scopus) from 2013 to 2023
Hirsch (H) index	20 (Scopus)

Part XII– Selected Publications

List of the publications selected for the evaluation. For each publication report title, authors, reference data, journal IF (if applicable), citations, press/media release (if any).

- 1) Cefalù AB*, **D'Erasmus L***, Iannuzzo G*, Noto D, Giammanco A, Montali A, Zambon A, Forte F, Suppressa P, Giannini S, Barbagallo CM, Ganci A, Nardi E, Vernuccio F, Caldarella R, Ciaccio M, Arca M, Averna M. Efficacy and safety of lomitapide in familial chylomicronaemia syndrome. *Atherosclerosis*. 2022 Oct;359:13-19. doi: 10.1016/j.atherosclerosis.2022.08.017. **(IF 6,851)**
* These authors contributed equally to the work.
- 2) **D'Erasmus L***, Giammanco A*, Suppressa P*, Pavanello C, Iannuzzo G, Di Costanzo A, Tramontano D, Minicocci I, Bini S, Vogt A, Stewards K, Roeters Van Lennep J, Bertolini S, Arca M; Italian and European Working Group on Lomitapide in HoFH. Efficacy of Long-Term Treatment of Autosomal Recessive Hypercholesterolemia With Lomitapide: A Subanalysis of the Pan-European Lomitapide Study. *Front Genet*. 2022 Aug 22;13:937750. doi: 10.3389/fgene.2022.937750. **(IF 4,772)**
* These authors contributed equally to the work.
- 3) Bini S, Pecce V, Di Costanzo A, Polito L, Ghadiri A, Minicocci I, Tambaro F, Covino S, Arca M, **D'Erasmus L**. The Fibrinogen-like Domain of ANGPTL3 Facilitates Lipolysis in 3T3-L1 Cells by Activating the Intracellular Erk Pathway. *Biomolecules*. 2022 Apr 16;12(4):585. doi: 10.3390/biom12040585. **(IF 8,526)**
- 4) Baratta F*, **D'Erasmus L***, Di Costanzo A, Umbro I, Pastori D, Angelico F, Del Ben M. Metabolic Syndrome but Not Fatty Liver-Associated Genetic Variants Correlates with Glomerular Renal Function Decline in Patients with Non-Alcoholic Fatty Liver Disease. *Biomedicines*. 2022 Mar 19;10(3):720. doi: 10.3390/biomedicines10030720. **(IF 6,064)**
* These authors contributed equally to the work.
- 5) **D'Erasmus L***, Steward K*, Cefalù AB, Di Costanzo A, Boersma E, Bini S, Arca M, van Lennep JR; Italian and European Working Group on Lomitapide in HoFH. Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study. *Eur J Prev Cardiol*. 2022 May 5;29(5):832-841. doi: 10.1093/eurjpc/zwab229. **(IF 8,526)**
* These authors contributed equally to the work.
- 6) **D'Erasmus L***, Gallo A*, Cefalù AB, Di Costanzo A, Saheb S, Giammanco A, Averna M, Buonaiuto A, Iannuzzo G, Fortunato G, Puja A, Montalcini T, Pavanello C, Calabresi L, Vigna GB, Bucci M, Bonomo K, Nota F, Sampietro T, Sbrana F, Suppressa P, Sabbà C, Fimiani F, Cesaro A, Calabrò P, Palmisano S, D'Addato S, Pisciotta L, Bertolini S, Bittar R, Kalmykova O, Béliard S, Carrié A, Arca M, Bruckert E. Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey. *Orphanet J Rare Dis*. 2021 Sep 8;16(1):381. doi: 10.1186/s13023-021-01999-8. **(IF 4,302)**

* These authors contributed equally to the work.

- 7) **D'Erasmus L***, Minicocci I*, Di Costanzo A, Pigna G, Commodari D, Ceci F, Montali A, Brancato F, Stanca I, Nicolucci A, Ascione A, Galea N, Carbone I, Francone M, Maranghi M, Arca M. Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Long-Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events. *J Am Heart Assoc.* 2021 May 4;10(9):e018932. doi: 10.1161/JAHA.120.018932. **(IF 6,107)**

* These authors contributed equally to the work

- 8) **D'Erasmus L**, Commodari D, Di Costanzo A, Minicocci I, Polito L, Ceci F, Montali A, Maranghi M, Arca M. Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: A retrospective, single center, observational study. *Nutr Metab Cardiovasc Dis.* 2020 Oct 30;30(11):2027-2035. doi: 10.1016/j.numecd.2020.06.028. **(IF 4,222)**

- 9) **D'Erasmus L***, Di Costanzo A*, Cassandra F, Minicocci I, Polito L, Montali A, Ceci F, Arca M. Spectrum of Mutations and Long-Term Clinical Outcomes in Genetic Chylomicronemia Syndromes. *Arterioscler Thromb Vasc Biol.* 2019 Dec;39(12):2531-2541. doi: 10.1161/ATVBAHA.119.313401. **(IF 6,604)**

* These authors contributed equally to the work.

- 10) **D'Erasmus L***, Minicocci I*, Nicolucci A, Pintus P, Roeters Van Lennep JE, Masana L, Mata P, Sánchez-Hernández RM, Prieto-Matos P, Real JT, Ascaso JF, Lafuente EE, Pocovi M, Fuentes FJ, Muntoni S, Bertolini S, Sirtori C, Calabresi L, Pavanello C, Averna M, Cefalu AB, Noto D, Pacifico AA, Pes GM, Harada-Shiba M, Manzato E, Zambon S, Zambon A, Vogt A, Scardapane M, Sjouke B, Fellin R, Arca M. Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes. *J Am Coll Cardiol.* 2018 Jan 23;71(3):279-288. doi: 10.1016/j.jacc.2017.11.028. **(IF 18,639)**

* These authors contributed equally to the work.

- 11) **D'Erasmus L**, Bini S, Arca M. Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS). *Curr Atheroscler Rep.* 2021 Sep 1;23(11):65. doi: 10.1007/s11883-021-00967-8. **(IF 5,967)**

- 12) **D'Erasmus L***, Di Costanzo A, Gallo A, Bruckert E, Arca M. ApoCIII: A multifaceted protein in cardiometabolic disease. *Metabolism.* 2020 Dec;113:154395. doi: 10.1016/j.metabol.2020.154395.

* These authors contributed equally to the work. **(IF 8,697)**

Part XII- Carrer Break

08/09/2020-22/04/2021	Maternity leave
-----------------------	-----------------

Avvertenza: il presente allegato costituisce uno schema-tipo, nel quale sono indicate alcune voci a mero titolo esemplificativo. Pertanto, il presente modello di *curriculum vitae* può essere modificato/integrato dal candidato adattandolo alle peculiarità della propria attività scientifico-professionale

Rome 21 June 23

Laura D'Erasmus